Literature DB >> 32100921

lncRNA TTN-AS1 facilitates proliferation, invasion, and epithelial-mesenchymal transition of breast cancer cells by regulating miR-139-5p/ZEB1 axis.

Jun Fang1, Chen Huang1, Jing Ke1, Jia Li1, Wei Zhang1, Huimin Xue1, Jinpeng Chen1.   

Abstract

Breast cancer is a common malignant tumor suffered predominantly by women worldwide, which results in serious levels of morbidity and mortality. To control the effects of the cancer, it is critically important to elucidate the pathophysiological processes by which it occurs and develops. Reports have demonstrated that long noncoding RNAs perform a critical role in the development and metastasis of cancers. The lncRNA TTN-AS1 is considered carcinogenic. Nevertheless, the importance and biological functions of TTN-AS1 in breast cancer require greater exploration. In the current paper, we observed that TTN-AS1 expression was significantly upregulated in breast cancer tissues/cells compared with those that are healthy. TTN-AS1 enhanced the proliferation, migration, invasion, and epithelial-mesenchymal transformation of breast cancer cells. Furthermore, a direct target of TTN-AS1, miR-139-5p was negatively regulated. In addition, zinc finger E-box binding homeobox 1 (ZEB1) is an important nuclear transcription factor, the expression of which is increased in multiple tumors. Here, we also found that ZEB1 is a target of miR-139-5p, of which TTN-AS1 could regulate the expression through competition with miR-139-5p. That is, TTN-AS1 promoted proliferation and invasion of breast cancer cells by interaction with the miR-139-5p/ZEB1 axis. In conclusion, the present study aimed to illustrate the significance of TTN-AS1 in breast cancer metastasis and contribute to potentially innovative strategies for its treatment.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  TTN-AS1; breast cancer; epithelial-mesenchymal transition; lncRNA; miR-139-5p

Year:  2020        PMID: 32100921     DOI: 10.1002/jcb.29700

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Long non-coding RNA TTN antisense RNA 1 facilitates hepatocellular carcinoma progression via regulating miR-139-5p/SPOCK1 axis.

Authors:  Xinghao Zhu; Shiqing Jiang; Zongyao Wu; Tonghua Liu; Wei Zhang; Lili Wu; Lijun Xu; Mingliang Shao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

2.  MiR-139-5p-ZEB1 is a Molecular Regulator of Growth, Invasion, and Epithelial-to-Mesenchymal Transition of Cervical Cancer.

Authors:  Jinrui Sun; Shanshan Wang; Ping Liu; Yulan Liu
Journal:  Cancer Manag Res       Date:  2020-12-10       Impact factor: 3.989

Review 3.  The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression.

Authors:  Lu Xia; Jingyun Chen; Min Huang; Jie Mei; Min Lin
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

4.  The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma.

Authors:  Yao Jun Li; Hai Yan Li; Quan Zhang; Sheng Li Wei
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

5.  Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing.

Authors:  Bingxian Bian; Li Li; Xing Ke; Hui Chen; Yi Liu; Naisheng Zheng; Yingxia Zheng; Yanhui Ma; Yunlan Zhou; Junyao Yang; Lanshu Xiao; Lisong Shen
Journal:  Front Oncol       Date:  2022-09-01       Impact factor: 5.738

6.  Circ_0072995 Promotes Cell Carcinogenesis via Up-Regulating miR-149-5p-Mediated SHMT2 in Breast Cancer.

Authors:  Chuang Qi; Xianxiong Qin; Zuozhi Zhou; Yan Wang; Qin Yang; Tianzhi Liao
Journal:  Cancer Manag Res       Date:  2020-11-03       Impact factor: 3.989

7.  Long non-coding RNA TTN-AS1/microRNA-199a-3p/runt-related transcription factor 1 gene axis regulates the progression of oral squamous cell carcinoma.

Authors:  Zhongzhi Jin; Shengjun Jiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.